Hubbry Logo
Enzyme inhibitorEnzyme inhibitorMain
Open search
Enzyme inhibitor
Community hub
Enzyme inhibitor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Enzyme inhibitor
Enzyme inhibitor
Enzyme inhibitor
View on Wikipedia
from Wikipedia

cartoon depiction of an enzyme binding substrate to its active site and releasing product (top), and an inhibitor binding to the active site, thus preventing substrate binding
Top: enzyme (E) accelerates conversion of substrates (S) to products (P). Bottom: by binding to the enzyme, inhibitor (I) blocks binding of substrate. Binding site shown in blue checkerboard, substrate as black rectangle, and inhibitor as green rounded rectangle.

An enzyme inhibitor is a molecule that binds to an enzyme and blocks its activity. Enzymes are proteins that speed up chemical reactions necessary for life, in which substrate molecules are converted into products.[1] An enzyme facilitates a specific chemical reaction by binding the substrate to its active site, a specialized area on the enzyme that accelerates the most difficult step of the reaction.

An enzyme inhibitor stops ("inhibits") this process, either by binding to the enzyme's active site (thus preventing the substrate itself from binding) or by binding to another site on the enzyme such that the enzyme's catalysis of the reaction is blocked. Enzyme inhibitors may bind reversibly or irreversibly. Irreversible inhibitors form a chemical bond with the enzyme such that the enzyme is inhibited until the chemical bond is broken. By contrast, reversible inhibitors bind non-covalently and may spontaneously leave the enzyme, allowing the enzyme to resume its function. Reversible inhibitors produce different types of inhibition depending on whether they bind to the enzyme, the enzyme-substrate complex, or both.

Enzyme inhibitors play an important role in all cells, since they are generally specific to one enzyme each and serve to control that enzyme's activity. For example, enzymes in a metabolic pathway may be inhibited by molecules produced later in the pathway, thus curtailing the production of molecules that are no longer needed. This type of negative feedback is an important way to maintain balance in a cell.[2] Enzyme inhibitors also control essential enzymes such as proteases or nucleases that, if left unchecked, may damage a cell. Many poisons produced by animals or plants are enzyme inhibitors that block the activity of crucial enzymes in prey or predators.

Many drug molecules are enzyme inhibitors that inhibit an aberrant human enzyme or an enzyme critical for the survival of a pathogen such as a virus, bacterium or parasite. Examples include methotrexate (used in chemotherapy and in treating rheumatic arthritis) and the protease inhibitors used to treat HIV/AIDS. Since anti-pathogen inhibitors generally target only one enzyme, such drugs are highly specific and generally produce few side effects in humans, provided that no analogous enzyme is found in humans. (This is often the case, since such pathogens and humans are genetically distant.) Medicinal enzyme inhibitors often have low dissociation constants, meaning that only a minute amount of the inhibitor is required to inhibit the enzyme. A low concentration of the enzyme inhibitor reduces the risk for liver and kidney damage and other adverse drug reactions in humans. Hence the discovery and refinement of enzyme inhibitors is an active area of research in biochemistry and pharmacology.

Structural classes

[edit]

Enzyme inhibitors are a chemically diverse set of substances that range in size from organic small molecules to macromolecular proteins.

Small molecule inhibitors include essential primary metabolites that inhibit upstream enzymes that produce those metabolites. This provides a negative feedback loop that prevents over production of metabolites and thus maintains cellular homeostasis (steady internal conditions).[3][2] Small molecule enzyme inhibitors also include secondary metabolites, which are not essential to the organism that produces them, but provide the organism with an evolutionary advantage, in that they can be used to repel predators or competing organisms or immobilize prey.[4] In addition, many drugs are small molecule enzyme inhibitors that target either disease-modifying enzymes in the patient[1]: 5  or enzymes in pathogens which are required for the growth and reproduction of the pathogen.[5]

In addition to small molecules, some proteins act as enzyme inhibitors. The most prominent example are serpins (serine protease inhibitors) which are produced by animals to protect against inappropriate enzyme activation and by plants to prevent predation.[6] Another class of inhibitor proteins is the ribonuclease inhibitors, which bind to ribonucleases in one of the tightest known protein–protein interactions.[7] A special case of protein enzyme inhibitors are zymogens that contain an autoinhibitory N-terminal peptide that binds to the active site of enzyme that intramolecularly blocks its activity as a protective mechanism against uncontrolled catalysis. The N‑terminal peptide is cleaved (split) from the zymogen enzyme precursor by another enzyme to release an active enzyme.[8]

The binding site of inhibitors on enzymes is most commonly the same site that binds the substrate of the enzyme. These active site inhibitors are known as orthosteric ("regular" orientation) inhibitors.[9] The mechanism of orthosteric inhibition is simply to prevent substrate binding to the enzyme through direct competition which in turn prevents the enzyme from catalysing the conversion of substrates into products. Alternatively, the inhibitor can bind to a site remote from the enzyme active site. These are known as allosteric ("alternative" orientation) inhibitors.[9] The mechanisms of allosteric inhibition are varied and include changing the conformation (shape) of the enzyme such that it can no longer bind substrate (kinetically indistinguishable from competitive orthosteric inhibition)[10] or alternatively stabilise binding of substrate to the enzyme but lock the enzyme in a conformation which is no longer catalytically active.[11]

Reversible inhibitors

[edit]
Inhibition mechanism schematic
chemical equilibrium reaction formula for competitive, uncompetitive, non-competitive, and mixed inhibition
Kinetic mechanisms for reversible inhibition. Substrate (S) binding to enzyme (E) in blue, catalysis releasing product (P) in red, inhibitor (I) binding to enzyme in green.
schematic diagram of the three types of reversible inhibitors
Schematics for reversible inhibition. Binding site in blue, substrate in black, inhibitor in green, and allosteric site in light green.
Competitive inhibitors usually bind to the active site. Non-competitive bind to a remote (allosteric) site. Uncompetitive inhibitors only bind once the substrate is bound, fully disrupting catalysis, and mixed inhibition is similar but with only partial disruption of catalysis.

Reversible inhibitors attach to enzymes with non-covalent interactions such as hydrogen bonds, hydrophobic interactions and ionic bonds.[12] Multiple weak bonds between the inhibitor and the enzyme active site combine to produce strong and specific binding.

In contrast to irreversible inhibitors, reversible inhibitors generally do not undergo chemical reactions when bound to the enzyme and can be easily removed by dilution or dialysis. A special case is covalent reversible inhibitors that form a chemical bond with the enzyme, but the bond can be cleaved so the inhibition is fully reversible.[13]

Reversible inhibitors are generally categorized into four types, as introduced by Cleland in 1963.[14] They are classified according to the effect of the inhibitor on the Vmax (maximum reaction rate catalysed by the enzyme) and Km (the concentration of substrate resulting in half maximal enzyme activity) as the concentration of the enzyme's substrate is varied.[15][16]

Competitive

[edit]

In competitive inhibition the substrate and inhibitor cannot bind to the enzyme at the same time.[17]: 134  This usually results from the inhibitor having an affinity for the active site of an enzyme where the substrate also binds; the substrate and inhibitor compete for access to the enzyme's active site. This type of inhibition can be overcome by sufficiently high concentrations of substrate (Vmax remains constant), i.e., by out-competing the inhibitor.[17]: 134–135  However, the apparent Km will increase as it takes a higher concentration of the substrate to reach the Km point, or half the Vmax. Competitive inhibitors are often similar in structure to the real substrate (see for example the "methotrexate versus folate" figure in the "Drugs" section).[17]: 134 

Uncompetitive

[edit]

In uncompetitive inhibition the inhibitor binds only to the enzyme-substrate complex.[17]: 139  This type of inhibition causes Vmax to decrease (maximum velocity decreases as a result of removing activated complex) and Km to decrease (due to better binding efficiency as a result of Le Chatelier's principle and the effective elimination of the ES complex thus decreasing the Km which indicates a higher binding affinity).[18] Uncompetitive inhibition is rare.[17]: 139 [19]

Non-competitive

[edit]

In non-competitive inhibition the binding of the inhibitor to the enzyme reduces its activity but does not affect the binding of substrate.[16] This type of inhibitor binds with equal affinity to the free enzyme as to the enzyme-substrate complex. It can be thought of as having the ability of competitive and uncompetitive inhibitors, but with no preference to either type. As a result, the extent of inhibition depends only on the concentration of the inhibitor. Vmax will decrease due to the inability for the reaction to proceed as efficiently, but Km will remain the same as the actual binding of the substrate, by definition, will still function properly.[20]

Mixed

[edit]

In mixed inhibition the inhibitor may bind to the enzyme whether or not the substrate has already bound. Hence mixed inhibition is a combination of competitive and noncompetitive inhibition.[16] Furthermore, the affinity of the inhibitor for the free enzyme and the enzyme-substrate complex may differ.[17]: 136–139  By increasing concentrations of substrate [S], this type of inhibition can be reduced (due to the competitive contribution), but not entirely overcome (due to the noncompetitive component).[21]: 381–382  Although it is possible for mixed-type inhibitors to bind in the active site, this type of inhibition generally results from an allosteric effect where the inhibitor binds to a different site on an enzyme. Inhibitor binding to this allosteric site changes the conformation (that is, the tertiary structure or three-dimensional shape) of the enzyme so that the affinity of the substrate for the active site is reduced.[22]

These four types of inhibition can also be distinguished by the effect of increasing the substrate concentration [S] on the degree of inhibition caused by a given amount of inhibitor. For competitive inhibition the degree of inhibition is reduced by increasing [S], for noncompetitive inhibition the degree of inhibition is unchanged, and for uncompetitive (also called anticompetitive) inhibition the degree of inhibition increases with [S].[23]

Quantitative description

[edit]

Reversible inhibition can be described quantitatively in terms of the inhibitor's binding to the enzyme and to the enzyme-substrate complex, and its effects on the kinetic constants of the enzyme.[24]: 6  In the classic Michaelis-Menten scheme (shown in the "inhibition mechanism schematic" diagram), an enzyme (E) binds to its substrate (S) to form the enzyme–substrate complex ES. Upon catalysis, this complex breaks down to release product P and free enzyme.[24]: 55  The inhibitor (I) can bind to either E or ES with the dissociation constants Ki or Ki', respectively.[24]: 87 

  • Competitive inhibitors can bind to E, but not to ES. Competitive inhibition increases Km (i.e., the inhibitor interferes with substrate binding), but does not affect Vmax (the inhibitor does not hamper catalysis in ES because it cannot bind to ES).[24]: 102 
  • Uncompetitive inhibitors bind to ES. Uncompetitive inhibition decreases both Km and Vmax. The inhibitor affects substrate binding by increasing the enzyme's affinity for the substrate (decreasing Km) as well as hampering catalysis (decreases Vmax).[24]: 106 
  • Non-competitive inhibitors have identical affinities for E and ES (Ki = Ki'). Non-competitive inhibition does not change Km (i.e., it does not affect substrate binding) but decreases Vmax (i.e., inhibitor binding hampers catalysis).[24]: 97 
  • Mixed-type inhibitors bind to both E and ES, but their affinities for these two forms of the enzyme are different (Ki ≠ Ki'). Thus, mixed-type inhibitors affect substrate binding (increase or decrease Km) and hamper catalysis in the ES complex (decrease Vmax).[25]: 63–64 

When an enzyme has multiple substrates, inhibitors can show different types of inhibition depending on which substrate is considered. This results from the active site containing two different binding sites within the active site, one for each substrate. For example, an inhibitor might compete with substrate A for the first binding site, but be a non-competitive inhibitor with respect to substrate B in the second binding site.[26]

Traditionally reversible enzyme inhibitors have been classified as competitive, uncompetitive, or non-competitive, according to their effects on Km and Vmax.[14] These three types of inhibition result respectively from the inhibitor binding only to the enzyme E in the absence of substrate S, to the enzyme–substrate complex ES, or to both. The division of these classes arises from a problem in their derivation and results in the need to use two different binding constants for one binding event.[27] It is further assumed that binding of the inhibitor to the enzyme results in 100% inhibition and fails to consider the possibility of partial inhibition.[27] The common form of the inhibitory term also obscures the relationship between the inhibitor binding to the enzyme and its relationship to any other binding term be it the Michaelis–Menten equation or a dose response curve associated with ligand receptor binding. To demonstrate the relationship the following rearrangement can be made:[28]

This rearrangement demonstrates that similar to the Michaelis–Menten equation, the maximal rate of reaction depends on the proportion of the enzyme population interacting with its substrate.

fraction of the enzyme population bound by substrate

fraction of the enzyme population bound by inhibitor

the effect of the inhibitor is a result of the percent of the enzyme population interacting with inhibitor. The only problem with this equation in its present form is that it assumes absolute inhibition of the enzyme with inhibitor binding, when in fact there can be a wide range of effects anywhere from 100% inhibition of substrate turn over to no inhibition. To account for this the equation can be easily modified to allow for different degrees of inhibition by including a delta Vmax term.[29]: 361 

or

This term can then define the residual enzymatic activity present when the inhibitor is interacting with individual enzymes in the population. However the inclusion of this term has the added value of allowing for the possibility of activation if the secondary Vmax term turns out to be higher than the initial term. To account for the possibly of activation as well the notation can then be rewritten replacing the inhibitor "I" with a modifier term (stimulator or inhibitor) denoted here as "X".[28]: eq 13 

While this terminology results in a simplified way of dealing with kinetic effects relating to the maximum velocity of the Michaelis–Menten equation, it highlights potential problems with the term used to describe effects relating to the Km. The Km relating to the affinity of the enzyme for the substrate should in most cases relate to potential changes in the binding site of the enzyme which would directly result from enzyme inhibitor interactions. As such a term similar to the delta Vmax term proposed above to modulate Vmax should be appropriate in most situations:[28]: eq 14 

Dissociation constants

[edit]
2D plots of 1/[S] concentration (x-axis) and 1/V (y-axis) demonstrating that as inhibitor concentration is changed, competitive inhibitor lines intersect at a single point on the y-axis, non-competitive inhibitors intersect at the x-axis, and mixed inhibitors intersect a point that is on neither axis
Lineweaver–Burk diagrams of different types of reversible enzyme inhibitors. The arrow shows the effect of increasing concentrations of inhibitor.

An enzyme inhibitor is characterised by its dissociation constant Ki, the concentration at which the inhibitor half occupies the enzyme. In non-competitive inhibition the inhibitor can also bind to the enzyme-substrate complex, and the presence of bound substrate can change the affinity of the inhibitor for the enzyme, resulting in a second dissociation constant Ki'. Hence Ki and Ki' are the dissociation constants of the inhibitor for the enzyme and to the enzyme-substrate complex, respectively.[30]: Glossary  The enzyme-inhibitor constant Ki can be measured directly by various methods; one especially accurate method is isothermal titration calorimetry, in which the inhibitor is titrated into a solution of enzyme and the heat released or absorbed is measured.[31] However, the other dissociation constant Ki' is difficult to measure directly, since the enzyme-substrate complex is short-lived and undergoing a chemical reaction to form the product. Hence, Ki' is usually measured indirectly, by observing the enzyme activity under various substrate and inhibitor concentrations, and fitting the data via nonlinear regression[32] to a modified Michaelis–Menten equation.[21]

where the modifying factors α and α' are defined by the inhibitor concentration and its two dissociation constants

Thus, in the presence of the inhibitor, the enzyme's effective Km and Vmax become (α/α')Km and (1/α')Vmax, respectively. However, the modified Michaelis-Menten equation assumes that binding of the inhibitor to the enzyme has reached equilibrium, which may be a very slow process for inhibitors with sub-nanomolar dissociation constants. In these cases the inhibition becomes effectively irreversible, hence it is more practical to treat such tight-binding inhibitors as irreversible (see below).

The effects of different types of reversible enzyme inhibitors on enzymatic activity can be visualised using graphical representations of the Michaelis–Menten equation, such as Lineweaver–Burk, Eadie-Hofstee or Hanes-Woolf plots.[17]: 140–144  An illustration is provided by the three Lineweaver–Burk plots depicted in the Lineweaver–Burk diagrams figure. In the top diagram the competitive inhibition lines intersect on the y-axis, illustrating that such inhibitors do not affect Vmax. In the bottom diagram the non-competitive inhibition lines intersect on the x-axis, showing these inhibitors do not affect Km. However, since it can be difficult to estimate Ki and Ki' accurately from such plots,[33] it is advisable to estimate these constants using more reliable nonlinear regression methods.[33]

Special cases

[edit]

Partially competitive

[edit]

The mechanism of partially competitive inhibition is similar to that of non-competitive, except that the EIS complex has catalytic activity, which may be lower or even higher (partially competitive activation) than that of the enzyme–substrate (ES) complex. This inhibition typically displays a lower Vmax, but an unaffected Km value.[18]

Substrate or product

[edit]

Substrate or product inhibition is where either an enzymes substrate or product also act as an inhibitor. This inhibition may follow the competitive, uncompetitive or mixed patterns. In substrate inhibition there is a progressive decrease in activity at high substrate concentrations, potentially from an enzyme having two competing substrate-binding sites. At low substrate, the high-affinity site is occupied and normal kinetics are followed. However, at higher concentrations, the second inhibitory site becomes occupied, inhibiting the enzyme.[34] Product inhibition (either the enzyme's own product, or a product to an enzyme downstream in its metabolic pathway) is often a regulatory feature in metabolism and can be a form of negative feedback.[2]

Slow-tight

[edit]

Slow-tight inhibition occurs when the initial enzyme–inhibitor complex EI undergoes conformational isomerism (a change in shape) to a second more tightly held complex, EI*, but the overall inhibition process is reversible. This manifests itself as slowly increasing enzyme inhibition. Under these conditions, traditional Michaelis–Menten kinetics give a false value for Ki, which is time–dependent. The true value of Ki can be obtained through more complex analysis of the on (kon) and off (koff) rate constants for inhibitor association with kinetics similar to irreversible inhibition.[17]: 168 

Multi-substrate analogues

[edit]
TGDDF / GDDF MAIs where blue depicts the tetrahydrofolate cofactor analogue, black GAR or thioGAR and red, the connecting atoms.
TGDDF/GDDF multi-substrate adduct inhibitor. Substrate analogue in black, cofactor analogue in blue, non-cleavable linker in red.
Ritonavir is similar to the natural substrate.
Peptide-based HIV-1 protease inhibitor ritonavir with substrate binding sites located in enzyme labelled as S2, S1, S1', and S2'.
Tipranavir is not similar to the natural substrate.
Nonpeptidic HIV-1 protease inhibitor tipranavir

Multi-substrate analogue inhibitors are high affinity selective inhibitors that can be prepared for enzymes that catalyse reactions with more than one substrate by capturing the binding energy of each of those substrate into one molecule.[35][36] For example, in the formyl transfer reactions of purine biosynthesis, a potent Multi-substrate Adduct Inhibitor (MAI) to glycinamide ribonucleotide (GAR) TFase was prepared synthetically by linking analogues of the GAR substrate and the N-10-formyl tetrahydrofolate cofactor together to produce thioglycinamide ribonucleotide dideazafolate (TGDDF),[37] or enzymatically from the natural GAR substrate to yield GDDF.[38] Here the subnanomolar dissociation constant (KD) of TGDDF was greater than predicted presumably due to entropic advantages gained and/or positive interactions acquired through the atoms linking the components. MAIs have also been observed to be produced in cells by reactions of pro-drugs such as isoniazid[39] or enzyme inhibitor ligands (for example, PTC124)[40] with cellular cofactors such as nicotinamide adenine dinucleotide (NADH) and adenosine triphosphate (ATP) respectively.[41]

Examples

[edit]

As enzymes have evolved to bind their substrates tightly, and most reversible inhibitors bind in the active site of enzymes, it is unsurprising that some of these inhibitors are strikingly similar in structure to the substrates of their targets. Inhibitors of dihydrofolate reductase (DHFR) are prominent examples.[42] Other examples of these substrate mimics are the protease inhibitors, a therapeutically effective class of antiretroviral drugs used to treat HIV/AIDS.[43][44] The structure of ritonavir, a peptidomimetic (peptide mimic) protease inhibitor containing three peptide bonds, as shown in the "competitive inhibition" figure above. As this drug resembles the peptide that is the substrate of the HIV protease, it competes with the substrate in the enzyme's active site.[45]

Enzyme inhibitors are often designed to mimic the transition state or intermediate of an enzyme-catalysed reaction.[46] This ensures that the inhibitor exploits the transition state stabilising effect of the enzyme, resulting in a better binding affinity (lower Ki) than substrate-based designs. An example of such a transition state inhibitor is the antiviral drug oseltamivir; this drug mimics the planar nature of the ring oxonium ion in the reaction of the viral enzyme neuraminidase.[47]

However, not all inhibitors are based on the structures of substrates. For example, the structure of another HIV protease inhibitor tipranavir is not based on a peptide and has no obvious structural similarity to a protein substrate. These non-peptide inhibitors can be more stable than inhibitors containing peptide bonds, because they will not be substrates for peptidases and are less likely to be degraded.[48]

In drug design it is important to consider the concentrations of substrates to which the target enzymes are exposed. For example, some protein kinase inhibitors have chemical structures that are similar to ATP, one of the substrates of these enzymes.[49] However, drugs that are simple competitive inhibitors will have to compete with the high concentrations of ATP in the cell. Protein kinases can also be inhibited by competition at the binding sites where the kinases interact with their substrate proteins, and most proteins are present inside cells at concentrations much lower than the concentration of ATP. As a consequence, if two protein kinase inhibitors both bind in the active site with similar affinity, but only one has to compete with ATP, then the competitive inhibitor at the protein-binding site will inhibit the enzyme more effectively.[50]

Irreversible inhibitors

[edit]

Types

[edit]
DFP reaction
2D structural diagram depicting a serine amino acid residue from the active site of the enzyme forming a covalent bond with DFP by displacing the fluoride atom
Reaction of the irreversible inhibitor diisopropylfluorophosphate (DFP) with a serine protease
Irreversible inhibitors bind to the enzyme's binding site then undergo a chemical reaction to form a covalent enzyme-inhibitor complex (EI*). Binding site in blue, inhibitor in green.

Irreversible inhibitors covalently bind to an enzyme, and this type of inhibition can therefore not be readily reversed.[51] Irreversible inhibitors often contain reactive functional groups such as nitrogen mustards, aldehydes, haloalkanes, alkenes, Michael acceptors, phenyl sulfonates, or fluorophosphonates.[52] These electrophilic groups react with amino acid side chains to form covalent adducts.[51] The residues modified are those with side chains containing nucleophiles such as hydroxyl or sulfhydryl groups; these include the amino acids serine (that reacts with DFP, see the "DFP reaction" diagram), and also cysteine, threonine, or tyrosine.[53]

Irreversible inhibition is different from irreversible enzyme inactivation.[54] Irreversible inhibitors are generally specific for one class of enzyme and do not inactivate all proteins; they do not function by destroying protein structure but by specifically altering the active site of their target. For example, extremes of pH or temperature usually cause denaturation of all protein structure, but this is a non-specific effect. Similarly, some non-specific chemical treatments destroy protein structure: for example, heating in concentrated hydrochloric acid will hydrolyse the peptide bonds holding proteins together, releasing free amino acids.[55]

Irreversible inhibitors display time-dependent inhibition and their potency therefore cannot be characterised by an IC50 value. This is because the amount of active enzyme at a given concentration of irreversible inhibitor will be different depending on how long the inhibitor is pre-incubated with the enzyme. Instead, kobs/[I] values are used,[56] where kobs is the observed pseudo-first order rate of inactivation (obtained by plotting the log of % activity versus time) and [I] is the concentration of inhibitor. The kobs/[I] parameter is valid as long as the inhibitor does not saturate binding with the enzyme (in which case kobs = kinact) where kinact is the rate of inactivation.

Measuring

[edit]
Irreversible inhibition mechanism
Depiction of the reversible chemical equilibria between enzyme + substrate, enzyme/substrate complex, and enzyme + product, and two competing equilibria. The first is between enzyme + inhibitor, enzyme/inhibitor non-covalent complex, followed by irreversible formation of the covalent complex. The second is between enzyme/substrate complex + inhibitor, noncovalent enzyme/substrate, followed by irreversible formation of the covalent complex
Kinetic mechanism for irreversible inhibition. Substrate binding in blue, catalysis in red, inhibitor binding in green, inactivation reaction in dark green.

Irreversible inhibitors first form a reversible non-covalent complex with the enzyme (EI or ESI). Subsequently, a chemical reaction occurs between the enzyme and inhibitor to produce the covalently modified "dead-end complex" EI* (an irreversible covalent complex). The rate at which EI* is formed is called the inactivation rate or kinact.[13] Since formation of EI may compete with ES, binding of irreversible inhibitors can be prevented by competition either with substrate or with a second, reversible inhibitor. This protection effect is good evidence of a specific reaction of the irreversible inhibitor with the active site.

The binding and inactivation steps of this reaction are investigated by incubating the enzyme with inhibitor and assaying the amount of activity remaining over time. The activity will be decreased in a time-dependent manner, usually following exponential decay. Fitting these data to a rate equation gives the rate of inactivation at this concentration of inhibitor. This is done at several different concentrations of inhibitor. If a reversible EI complex is involved the inactivation rate will be saturable and fitting this curve will give kinact and Ki.[57]

Another method that is widely used in these analyses is mass spectrometry. Here, accurate measurement of the mass of the unmodified native enzyme and the inactivated enzyme gives the increase in mass caused by reaction with the inhibitor and shows the stoichiometry of the reaction.[58] This is usually done using a MALDI-TOF mass spectrometer.[59] In a complementary technique, peptide mass fingerprinting involves digestion of the native and modified protein with a protease such as trypsin. This will produce a set of peptides that can be analysed using a mass spectrometer. The peptide that changes in mass after reaction with the inhibitor will be the one that contains the site of modification.[60]

Slow binding

[edit]
2D chemical structure diagram depicting a lysine residue from the enzyme first reacting with DFMO, elimination of fluoride and carbon dioxide, followed by cysteine attacking the covalent lysine-DFMO adduct freeing the lysine residue to form an irreversible cysteine adduct
Chemical mechanism for irreversible inhibition of ornithine decarboxylase by DFMO. Pyridoxal 5'-phosphate (Py) and enzyme (E) are not shown. Adapted from Poulin et al, 1992.[61]

Not all irreversible inhibitors form covalent adducts with their enzyme targets. Some reversible inhibitors bind so tightly to their target enzyme that they are essentially irreversible. These tight-binding inhibitors may show kinetics similar to covalent irreversible inhibitors. In these cases some of these inhibitors rapidly bind to the enzyme in a low-affinity EI complex and this then undergoes a slower rearrangement to a very tightly bound EI* complex (see the "irreversible inhibition mechanism" diagram). This kinetic behaviour is called slow-binding.[62] This slow rearrangement after binding often involves a conformational change as the enzyme "clamps down" around the inhibitor molecule. Examples of slow-binding inhibitors include some important drugs, such methotrexate,[63] allopurinol,[64] and the activated form of acyclovir.[65]

Some examples

[edit]
3D cartoon diagram of the trypanothione reductase protein bound to two molecules of inhibitors depicted as a stick diagrams.
Trypanothione reductase with the lower molecule of an inhibitor bound irreversibly and the upper one reversibly. Created from Bond et al, 2004.[66] (PDB: 1GXF​)

Diisopropylfluorophosphate (DFP) is an example of an irreversible protease inhibitor (see the "DFP reaction" diagram). The enzyme hydrolyses the phosphorus–fluorine bond, but the phosphate residue remains bound to the serine in the active site, deactivating it.[67] Similarly, DFP also reacts with the active site of acetylcholine esterase in the synapses of neurons, and consequently is a potent neurotoxin, with a lethal dose of less than 100 mg.[68]

Suicide inhibition is an unusual type of irreversible inhibition where the enzyme converts the inhibitor into a reactive form in its active site.[69] An example is the inhibitor of polyamine biosynthesis, α-difluoromethylornithine (DFMO), which is an analogue of the amino acid ornithine, and is used to treat African trypanosomiasis (sleeping sickness). Ornithine decarboxylase can catalyse the decarboxylation of DFMO instead of ornithine (see the "DFMO inhibitor mechanism" diagram). However, this decarboxylation reaction is followed by the elimination of a fluorine atom, which converts this catalytic intermediate into a conjugated imine, a highly electrophilic species. This reactive form of DFMO then reacts with either a cysteine or lysine residue in the active site to irreversibly inactivate the enzyme.[61]

Since irreversible inhibition often involves the initial formation of a non-covalent enzyme inhibitor (EI) complex,[13] it is sometimes possible for an inhibitor to bind to an enzyme in more than one way. For example, in the figure showing trypanothione reductase from the human protozoan parasite Trypanosoma cruzi, two molecules of an inhibitor called quinacrine mustard are bound in its active site. The top molecule is bound reversibly, but the lower one is bound covalently as it has reacted with an amino acid residue through its nitrogen mustard group.[70]

Applications

[edit]

Enzyme inhibitors are found in nature[71] and also produced artificially in the laboratory.[72] Naturally occurring enzyme inhibitors regulate many metabolic processes and are essential for life.[3][1] In addition, naturally produced poisons are often enzyme inhibitors that have evolved for use as toxic agents against predators, prey, and competing organisms.[4] These natural toxins include some of the most poisonous substances known.[73] Artificial inhibitors are often used as drugs, but can also be insecticides such as malathion, herbicides such as glyphosate,[74] or disinfectants such as triclosan. Other artificial enzyme inhibitors block acetylcholinesterase, an enzyme which breaks down acetylcholine, and are used as nerve agents in chemical warfare.[75]

Metabolic regulation

[edit]

Enzyme inhibition is a common feature of metabolic pathway control in cells.[3] Metabolic flux through a pathway is often regulated by a pathway's metabolites acting as inhibitors and enhancers for the enzymes in that same pathway. The glycolytic pathway is a classic example.[76] This catabolic pathway consumes glucose and produces ATP, NADH and pyruvate. A key step for the regulation of glycolysis is an early reaction in the pathway catalysed by phosphofructokinase‑1 (PFK1). When ATP levels rise, ATP binds an allosteric site in PFK1 to decrease the rate of the enzyme reaction; glycolysis is inhibited and ATP production falls. This negative feedback control helps maintain a steady concentration of ATP in the cell. However, metabolic pathways are not just regulated through inhibition since enzyme activation is equally important. With respect to PFK1, fructose 2,6-bisphosphate and ADP are examples of metabolites that are allosteric activators.[77]

Physiological enzyme inhibition can also be produced by specific protein inhibitors. This mechanism occurs in the pancreas, which synthesises many digestive precursor enzymes known as zymogens. Many of these are activated by the trypsin protease, so it is important to inhibit the activity of trypsin in the pancreas to prevent the organ from digesting itself. One way in which the activity of trypsin is controlled is the production of a specific and potent trypsin inhibitor protein in the pancreas. This inhibitor binds tightly to trypsin, preventing the trypsin activity that would otherwise be detrimental to the organ.[78] Although the trypsin inhibitor is a protein, it avoids being hydrolysed as a substrate by the protease by excluding water from trypsin's active site and destabilising the transition state.[79] Other examples of physiological enzyme inhibitor proteins include the barstar inhibitor of the bacterial ribonuclease barnase.[80]

Natural poisons

[edit]
photo of three piles of legume seeds coloured brown, pea green, and brown/orange
To discourage seed predation, legumes contain trypsin inhibitors that interfere with digestion.

Animals and plants have evolved to synthesise a vast array of poisonous products including secondary metabolites,[81] peptides and proteins[82] that can act as inhibitors. Natural toxins are usually small organic molecules and are so diverse that there are probably natural inhibitors for most metabolic processes.[83] The metabolic processes targeted by natural poisons encompass more than enzymes in metabolic pathways and can also include the inhibition of receptor, channel and structural protein functions in a cell. For example, paclitaxel (taxol), an organic molecule found in the Pacific yew tree, binds tightly to tubulin dimers and inhibits their assembly into microtubules in the cytoskeleton.[84]

Many natural poisons act as neurotoxins that can cause paralysis leading to death and function for defence against predators or in hunting and capturing prey. Some of these natural inhibitors,[85] despite their toxic attributes, are valuable for therapeutic uses at lower doses.[86] An example of a neurotoxin are the glycoalkaloids, from the plant species in the family Solanaceae (includes potato, tomato and eggplant), that are acetylcholinesterase inhibitors. Inhibition of this enzyme causes an uncontrolled increase in the acetylcholine neurotransmitter, muscular paralysis and then death. Neurotoxicity can also result from the inhibition of receptors; for example, atropine from deadly nightshade (Atropa belladonna) that functions as a competitive antagonist of the muscarinic acetylcholine receptors.[87]

Although many natural toxins are secondary metabolites, these poisons also include peptides and proteins. An example of a toxic peptide is alpha-amanitin, which is found in relatives of the death cap mushroom. This is a potent enzyme inhibitor, in this case preventing the RNA polymerase II enzyme from transcribing DNA.[88] The algal toxin microcystin is also a peptide and is an inhibitor of protein phosphatases.[89] This toxin can contaminate water supplies after algal blooms and is a known carcinogen that can also cause acute liver haemorrhage and death at higher doses.[90]

Proteins can also be natural poisons or antinutrients, such as the trypsin inhibitors (discussed in the "metabolic regulation" section above) that are found in some legumes.[91] A less common class of toxins are toxic enzymes: these act as irreversible inhibitors of their target enzymes and work by chemically modifying their substrate enzymes. An example is ricin, an extremely potent protein toxin found in castor oil beans.[92] This enzyme is a glycosidase that inactivates ribosomes.[93] Since ricin is a catalytic irreversible inhibitor, this allows just a single molecule of ricin to kill a cell.[94]

Drugs

[edit]
2D chemical structural diagrams comparing folic acid and methotrexate
The coenzyme folic acid (top) compared to the anti-cancer drug methotrexate (bottom)
2D structural diagram of sildenafil
The structure of sildenafil (Viagra)

The most common uses for enzyme inhibitors are as drugs to treat disease. Many of these inhibitors target a human enzyme and aim to correct a pathological condition. For instance, aspirin is a widely used drug that acts as a suicide inhibitor of the cyclooxygenase enzyme.[95] This inhibition in turn suppresses the production of proinflammatory prostaglandins and thus aspirin may be used to reduce pain, fever, and inflammation.[95]

As of 2017, an estimated 29% of approved drugs are enzyme inhibitors[96] of which approximately one-fifth are kinase inhibitors.[96] A notable class of kinase drug targets is the receptor tyrosine kinases which are essential enzymes that regulate cell growth; their over-activation may result in cancer. Hence kinase inhibitors such as imatinib are frequently used to treat malignancies.[97] Janus kinases are another notable example of drug enzyme targets. Inhibitors of Janus kinases block the production of inflammatory cytokines and hence these inhibitors are used to treat a variety of inflammatory diseases in including arthritis, asthma, and Crohn's disease.[98]

An example of the structural similarity of some inhibitors to the substrates of the enzymes they target is seen in the figure comparing the drug methotrexate to folic acid. Folic acid is the oxidised form of the substrate of dihydrofolate reductase, an enzyme that is potently inhibited by methotrexate. Methotrexate blocks the action of dihydrofolate reductase and thereby halts thymidine biosynthesis.[42] This block of nucleotide biosynthesis is selectively toxic to rapidly growing cells, therefore methotrexate is often used in cancer chemotherapy.[99]

A common treatment for erectile dysfunction is sildenafil (Viagra).[100] This compound is a potent inhibitor of cGMP specific phosphodiesterase type 5, the enzyme that degrades the signalling molecule cyclic guanosine monophosphate.[101] This signalling molecule triggers smooth muscle relaxation and allows blood flow into the corpus cavernosum, which causes an erection. Since the drug decreases the activity of the enzyme that halts the signal, it makes this signal last for a longer period of time.

Antibiotics

[edit]
3D cartoon diagram of transpeptidase bound to penicillin G depicted as sticks
The structure of a complex between penicillin G and the Streptomyces transpeptidase (PDB: 1PWC​)

Drugs are also used to inhibit enzymes needed for the survival of pathogens. For example, bacteria are surrounded by a thick cell wall made of a net-like polymer called peptidoglycan. Many antibiotics such as penicillin and vancomycin inhibit the enzymes that produce and then cross-link the strands of this polymer together.[102][103] This causes the cell wall to lose strength and the bacteria to burst. In the figure, a molecule of penicillin (shown in a ball-and-stick form) is shown bound to its target, the transpeptidase from the bacteria Streptomyces R61 (the protein is shown as a ribbon diagram).

Antibiotic drug design is facilitated when an enzyme that is essential to the pathogen's survival is absent or very different in humans.[104] Humans do not make peptidoglycan, therefore antibiotics that inhibit this process are selectively toxic to bacteria.[105] Selective toxicity is also produced in antibiotics by exploiting differences in the structure of the ribosomes in bacteria,[106] or how they make fatty acids.[107]

Antivirals

[edit]

Drugs that inhibit enzymes needed for the replication of viruses are effective in treating viral infections.[108] Antiviral drugs include protease inhibitors used to treat HIV/AIDS[109] and Hepatitis C,[110] reverse-transcriptase inhibitors targeting HIV/AIDS,[111] neuraminidase inhibitors targeting influenza,[112] and terminase inhibitors targeting human cytomegalovirus.[113]

Pesticides

[edit]

Many pesticides are enzyme inhibitors.[114] Acetylcholinesterase (AChE) is an enzyme found in animals, from insects to humans. It is essential to nerve cell function through its mechanism of breaking down the neurotransmitter acetylcholine into its constituents, acetate and choline.[115] This is somewhat unusual among neurotransmitters as most, including serotonin, dopamine, and norepinephrine, are absorbed from the synaptic cleft rather than cleaved. A large number of AChE inhibitors are used in both medicine and agriculture.[116] Reversible competitive inhibitors, such as edrophonium, physostigmine, and neostigmine, are used in the treatment of myasthenia gravis[117] and in anaesthesia to reverse muscle blockade.[118] The carbamate pesticides are also examples of reversible AChE inhibitors. The organophosphate pesticides such as malathion, parathion, and chlorpyrifos irreversibly inhibit acetylcholinesterase.[119]

Herbicides

[edit]

The herbicide glyphosate is an inhibitor of 3-phosphoshikimate 1-carboxyvinyltransferase,[120] other herbicides, such as the sulfonylureas inhibit the enzyme acetolactate synthase.[121] Both enzymes are needed for plants to make branched-chain amino acids. Many other enzymes are inhibited by herbicides, including enzymes needed for the biosynthesis of lipids and carotenoids and the processes of photosynthesis and oxidative phosphorylation.[122]

Discovery and design

[edit]
photo of robots at work
Robots are used for the high-throughput screening of chemical libraries to discover new enzyme inhibitors.

New drugs are the products of a long drug development process, the first step of which is often the discovery of a new enzyme inhibitor.[123] There are two principle approaches of discovering these inhibitors.[124]

The first general method is rational drug design based on mimicking the transition state of the chemical reaction catalysed by the enzyme.[125] The designed inhibitor often closely resembles the substrate, except that the portion of the substrate that undergoes chemical reaction is replaced by a chemically stable functional group that resembles the transition state. Since the enzyme has evolved to stabilise the transition state, transition state analogues generally possess higher affinity for the enzyme compared to the substrate, and therefore are effective inhibitors.[46]

The second way of discovering new enzyme inhibitors is high-throughput screening of large libraries of structurally diverse compounds to identify hit molecules that bind to the enzyme. This method has been extended to include virtual screening of databases of diverse molecules using computers,[126][127] which are then followed by experimental confirmation of binding of the virtual screening hits.[128] Complementary approaches that can provide new starting points for inhibitors include fragment-based lead discovery[129] and DNA Encoded Chemical Libraries (DEL).[130]

Hits from any of the above approaches can be optimised to high affinity binders that efficiently inhibit the enzyme.[131] Computer-based methods for predicting the binding orientation and affinity of an inhibitor for an enzyme such as molecular docking[132] and molecular mechanics can be used to assist in the optimisation process.[133] New inhibitors are used to obtain crystallographic structures of the enzyme in an inhibitor/enzyme complex to show how the molecule is binding to the active site, allowing changes to be made to the inhibitor to optimise binding in a process known as structure-based drug design.[1]: 66  This test and improve cycle is repeated until a sufficiently potent inhibitor is produced.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Enzyme inhibitor

View on Grokipedia
from Grokipedia
An inhibitor is a that binds to an , thereby decreasing its catalytic activity and interfering with the 's ability to convert substrates into products. These inhibitors can act reversibly, through non-covalent interactions that allow dissociation, or irreversibly, via covalent modifications that permanently disable the . By modulating function, inhibitors play crucial roles in regulating metabolic pathways, cellular signaling, and physiological processes. Enzyme inhibitors are classified primarily by their binding mechanisms and effects on , with reversible inhibition encompassing competitive, non-competitive, uncompetitive, and mixed types. Competitive inhibitors bind to the enzyme's , competing directly with the substrate and increasing the apparent Michaelis constant (Km) while leaving the maximum velocity (Vmax) unchanged; examples include , which inhibits . Non-competitive inhibitors bind to an allosteric site on the enzyme, reducing Vmax without affecting Km. Uncompetitive inhibitors bind only to the enzyme-substrate complex, decreasing both Km and Vmax, while mixed inhibitors affect both free enzyme and enzyme-substrate complex, altering both parameters variably. Irreversible inhibitors, such as aspirin acetylating (COX), form stable covalent bonds that inactivate the enzyme until new synthesis occurs. In and , enzyme inhibitors are foundational to therapeutic strategies, targeting dysregulated enzymes in diseases like , cancer, and infections. For instance, (ACE) inhibitors like block the conversion of angiotensin I to II, reducing and treating . Statins, such as , competitively inhibit to lower levels, exemplifying their role in preventing . Beyond therapeutics, inhibitors aid in understanding enzyme mechanisms and serve as tools in and to control pests or enhance crop yields.

Fundamentals

Definition and Biological Role

An is a that binds to an and decreases its catalytic activity by interfering with the enzyme's function. These inhibitors are essential for regulating biological processes, including metabolic pathways, , and the prevention of excessive enzymatic reactions that could disrupt cellular balance. In biological systems, inhibitors maintain by modulating activity in response to cellular needs; a key mechanism is feedback inhibition, where the end product of a binds to and inhibits an upstream , thereby preventing overproduction. For example, in , ATP acts as an endogenous inhibitor of phosphofructokinase-1, signaling high energy availability and slowing the pathway to conserve resources. Such natural inhibitors, often metabolites like ATP, are integral to endogenous , while synthetic inhibitors are engineered for applications in and to target specific enzymes. The recognition of enzyme inhibitors emerged in the early 20th century through foundational studies in by and , who in 1913 demonstrated effects such as product inhibition while analyzing activity.

General Mechanism of Inhibition

Enzyme inhibitors interact with enzymes primarily through binding at the , where normally occurs, or at allosteric sites distant from the , or via covalent modification of residues. Binding to the directly competes with or blocks substrate access, while allosteric binding influences the enzyme's function remotely, and covalent modification alters the enzyme's structure permanently. These interactions are fundamental to how inhibitors modulate enzymatic activity, with the active site serving as the primary locus for substrate recognition and transformation through precise spatial and chemical complementarity. Affinity refers to the strength of the enzyme-inhibitor interaction, determining how effectively the inhibitor occupies the ; specificity denotes the inhibitor's ability to target a particular over others, while selectivity describes its preference for one isoform or family member amid structurally similar targets. Upon binding, inhibitors often induce conformational changes in the , shifting it from an active to an inactive state by altering the active site's geometry or accessibility, thereby disrupting the catalytic machinery. These changes can propagate through the , highlighting the dynamic nature of enzyme function. The distinction between reversible and irreversible inhibition lies in the nature of the binding: reversible inhibition involves non-covalent interactions, such as hydrogen bonding, electrostatic forces, or hydrophobic effects, allowing the inhibitor to dissociate and restore activity over time. In contrast, irreversible inhibition forms stable covalent bonds, typically with reactive groups in the or elsewhere, leading to permanent inactivation that requires new synthesis for recovery. Conceptually, inhibition impacts reaction velocity by reducing the proportion of available for substrate binding and , resulting in a lower maximum rate of product formation compared to the uninhibited reaction. For illustration, envision a simple showing an molecule with its open to substrate (high velocity path) versus occupied or altered by an inhibitor (low velocity path), where the overall reaction progress curve flattens earlier or rises more slowly, emphasizing the inhibitor's role in slowing metabolic flux.

Reversible Inhibition

Competitive Inhibition

Competitive inhibition occurs when an inhibitor binds reversibly to the of the free (E), forming an enzyme-inhibitor (EI) complex that prevents the substrate (S) from binding and thus blocks the formation of the enzyme-substrate (ES) complex necessary for . This binding is non-covalent and competitive, as the inhibitor and substrate vie for the same site, with the outcome depending on their relative concentrations and affinities. In terms of , competitive inhibition increases the apparent Michaelis constant (Km), reflecting a reduced affinity of the for the substrate due to the inhibitor's occupation of the , while the maximum velocity (Vmax) remains unchanged because high substrate concentrations can outcompete the inhibitor and saturate all molecules. The velocity (v) of the inhibited reaction follows the modified Michaelis-Menten equation: v=Vmax⁡[S]Km(1+[I]Ki)+[S]v = \frac{V_{\max} [S]}{K_m (1 + \frac{[I]}{K_i}) + [S]} where [S] is the substrate concentration, [I] is the inhibitor concentration, and Ki is the inhibition constant representing the inhibitor's dissociation equilibrium constant from the EI complex. This equation derives from the steady-state assumption in reversible binding, highlighting how the apparent Km is elevated by the factor (1 + [I]/Ki). Structurally, competitive inhibitors often mimic the substrate's shape and chemical features to bind effectively to the , with particularly potent examples being transition state analogs that resemble the high-energy intermediate formed during , thereby achieving tighter binding than simple substrate mimics. These analogs exploit the enzyme's evolved affinity for the , leading to low Ki values in the nanomolar range. A prominent example is the class of drugs known as statins, which competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A () reductase, the rate-limiting enzyme in biosynthesis, by structurally resembling the substrate and binding to its . This inhibition reduces hepatic cholesterol production, upregulating receptors to lower circulating levels, as demonstrated in clinical studies showing significant reductions in cardiovascular risk.

Uncompetitive Inhibition

Uncompetitive inhibition is a form of reversible enzyme inhibition in which the inhibitor binds exclusively to the enzyme-substrate (ES) complex, forming an inactive ternary ESI complex that prevents the formation of product. This binding occurs at a site distinct from the active site, often becoming accessible only after substrate binding induces a conformational change in the enzyme. Unlike competitive inhibition, where the inhibitor competes with substrate for the free enzyme, uncompetitive inhibitors have no affinity for the free enzyme (E) and thus require prior substrate association. This mechanism is particularly prevalent in enzymes catalyzing multi-substrate reactions, especially those following ordered sequential or ping-pong bi-bi mechanisms, where the inhibitor mimics a subsequent substrate or product and binds only after the first substrate has associated. In such systems, product inhibition often manifests as uncompetitive with respect to the leading substrate, as the product binds preferentially to the central complexes (e.g., EQ in an ordered bi-bi reaction). Uncompetitive inhibitors frequently resemble the chemical structure of products or late-stage intermediates in the reaction pathway, exploiting interactions that stabilize the ES complex and trap it in a non-productive state.97864-6/fulltext) In terms of , reduces both the apparent Michaelis constant (KmappK_m^{app}) and the maximum velocity (VmaxappV_{max}^{app}) by the same factor, (1+[I]Ki)\left(1 + \frac{[I]}{K_i}\right), where [I][I] is the inhibitor concentration and KiK_i is the for the ESI complex. This proportional decrease enhances the enzyme's apparent affinity for the substrate (lower KmappK_m^{app}) while lowering the overall catalytic rate, resulting in on a Lineweaver-Burk double-reciprocal plot. The modified Michaelis-Menten equation describing the initial velocity (vv) under is: v=Vmax⁡[S]Km+[S](1+[I]Ki)v = \frac{V_{\max} [S]}{K_m + [S] \left(1 + \frac{[I]}{K_i}\right)} This equation arises from the steady-state assumption, where the inhibitor effectively sequesters ES into ESI, reducing the pool of productive complexes.39978-7/pdf) Although uncompetitive inhibition is theoretically possible in single-substrate enzymes, it is rare in practice because the low concentration of ES at subsaturating substrate levels limits inhibitor binding efficacy, making it a mostly hypothetical scenario for such systems.39978-7/pdf) A notable exception is the inhibition of intestinal alkaline phosphatase by L-phenylalanine, which acts as a stereospecific uncompetitive inhibitor with respect to phosphate ester substrates like p-nitrophenyl phosphate.96570-1/fulltext) Kinetic studies show that L-phenylalanine binds to the ES complex with a KiK_i of approximately 2.5 mM at pH 8.0, reducing both KmK_m and VmaxV_{max} without affecting the free enzyme, and the inhibition is pH-dependent, varying from negligible at pH 7.8 to about 66% at pH 9.8.96570-1/fulltext) This example highlights the utility of uncompetitive inhibition in regulating hydrolase activity in biological contexts.

Non-competitive and Mixed Inhibition

Non-competitive inhibition involves the binding of an inhibitor to an allosteric site on the , distinct from the , with equal affinity for both the free (E) and the enzyme-substrate complex (ES). This binding reduces the enzyme's catalytic efficiency by decreasing the maximum reaction velocity (Vmax⁡V_{\max}) while leaving the Michaelis constant (KmK_m), which reflects substrate affinity, unchanged. The mechanism typically induces a conformational change in the enzyme that impairs its ability to convert substrate to product, without interfering with substrate binding.90212-8) The kinetic equation for derives from the steady-state assumption and can be expressed as: v=Vmax⁡[S](Km+[S])(1+[I]Ki)v = \frac{V_{\max} [S]}{(K_m + [S]) \left(1 + \frac{[I]}{K_i}\right)} where vv is the reaction , [S][S] is the substrate concentration, [I][I] is the inhibitor concentration, and KiK_i is the for the enzyme-inhibitor complex. This form shows that the inhibitor effectively lowers Vmax⁡V_{\max} by a factor of 1+[I]/Ki1 + [I]/K_i, while the apparent KmK_m remains constant, leading to intersecting Lineweaver-Burk plots at the x-intercept.90212-8) Mixed inhibition extends the non-competitive model by allowing the inhibitor to bind with different affinities to E and ES, resulting in changes to both Vmax⁡V_{\max} and KmK_m. In this case, the inhibitor's interaction alters substrate binding affinity (affecting KmK_m) in addition to catalytic rate (affecting Vmax⁡V_{\max}), often through allosteric effects that propagate conformational changes across the structure. Pure represents a special case of where the affinities are identical (α=1\alpha = 1). The general for is: v=Vmax⁡[S]Km(1+[I]Ki)+[S](1+[I]αKi)v = \frac{V_{\max} [S]}{K_m \left(1 + \frac{[I]}{K_i}\right) + [S] \left(1 + \frac{[I]}{\alpha K_i}\right)} Here, α\alpha quantifies the relative affinity change; if α>1\alpha > 1, the inhibitor binds more tightly to E than to ES, increasing apparent KmK_m, whereas α<1\alpha < 1 indicates tighter binding to ES, decreasing apparent KmK_m. Lineweaver-Burk plots for mixed inhibition show lines intersecting neither on the x- nor y-axis.90212-8) An illustrative example of non-competitive inhibition is the action of heavy metals such as mercury, which bind to sulfhydryl groups at allosteric sites on enzymes like , inducing conformational changes that reduce catalytic activity without competing with substrates. This type of inhibition is common in environmental toxicology, where mercury exposure disrupts multiple enzyme functions through such allosteric interactions.

Quantitative Description

The quantitative analysis of reversible enzyme inhibition relies on extensions of the Michaelis-Menten equation, which describes uninhibited enzyme kinetics as v=Vmax⁡[S]Km+[S]v = \frac{V_{\max} [S]}{K_m + [S]}, where vv is the initial reaction velocity, Vmax⁡V_{\max} is the maximum velocity, [S][S] is the substrate concentration, and KmK_m is the Michaelis constant. To incorporate inhibition, the general equation for reversible inhibition is derived by considering the equilibria between free enzyme, enzyme-substrate complex, and enzyme-inhibitor complexes in steady-state kinetics. Assuming the inhibitor binds to free enzyme with dissociation constant KicK_{ic} and to the enzyme-substrate complex with KiuK_{iu}, the fraction of enzyme in the productive form is adjusted, yielding the unified form: v=Vmax⁡[S]Km(1+[I]Kic)+[S](1+[I]Kiu),v = \frac{V_{\max} [S]}{K_m \left(1 + \frac{[I]}{K_{ic}}\right) + [S] \left(1 + \frac{[I]}{K_{iu}}\right)}, where [I][I] is the inhibitor concentration. This equation encompasses all reversible inhibition types as special cases: when Kic=KiuK_{ic} = K_{iu}, it simplifies to non-competitive; when Kiu→∞K_{iu} \to \infty, competitive; and when Kic→∞K_{ic} \to \infty, uncompetitive.39978-7/fulltext) Lineweaver-Burk plots, obtained by taking the double reciprocal of the Michaelis-Menten equation (1v=KmVmax⁡⋅1[S]+1Vmax⁡\frac{1}{v} = \frac{K_m}{V_{\max}} \cdot \frac{1}{[S]} + \frac{1}{V_{\max}}), linearize the data as 1v\frac{1}{v} versus 1[S]\frac{1}{[S]}, allowing visual diagnosis of inhibition type through changes in slope and intercepts with varying [I]. In the presence of inhibitor, the plot follows 1v=Km(1+[I]/Kic)Vmax⁡⋅1[S]+1+[I]/KiuVmax⁡\frac{1}{v} = \frac{K_m (1 + [I]/K_{ic})}{V_{\max}} \cdot \frac{1}{[S]} + \frac{1 + [I]/K_{iu}}{V_{\max}}. For competitive inhibition, lines intersect on the y-axis (unchanged 1/Vmax⁡1/V_{\max}); for uncompetitive, lines are parallel (same slope ratio); for non-competitive, lines intersect on the x-axis (unchanged −1/Km-1/K_m); and for mixed, lines intersect neither on the axes nor parallel. These patterns provide a diagnostic framework for distinguishing inhibition mechanisms without direct measurement of binding constants. The half-maximal inhibitory concentration (IC50) quantifies inhibitor potency as the [I] reducing velocity to 50% of uninhibited value at a given [S]. It relates to the inhibition constant KiK_i via the Cheng-Prusoff equation, which for under conditions where [S] ≈ KmK_m approximates IC50 ≈ KiK_i, but generally IC50 = Ki(1+[S]/Km)K_i (1 + [S]/K_m), highlighting IC50's dependence on conditions unlike the intrinsic KiK_i. For other types, similar relations hold: uncompetitive IC50 = Kiu(1+Km/[S])K_{iu} (1 + K_m/[S]); non-competitive IC50 = KiK_i. This connection enables estimation of KiK_i from IC50 data when [S] and KmK_m are known, facilitating high-throughput screening.90196-2) Quantification of inhibition parameters is influenced by environmental factors that alter enzyme conformation, binding affinities, or reaction rates. pH affects KiK_i by modulating ionization states of and inhibitor residues critical for binding, often shifting optimal KiK_i values within the enzyme's pH activity profile (typically 5-9 for most enzymes). impacts KiK_i through van't Hoff effects on equilibrium constants and Arrhenius kinetics on rates, with increases generally lowering apparent KiK_i up to the denaturation threshold (around 40-60°C for mesophilic enzymes), beyond which irreversible unfolding raises it. Enzyme concentration ([E]) minimally affects KiK_i in classical rapid-equilibrium cases where [I] >> [E], but for tight-binding inhibitors (where KiK_i ≈ [E]), apparent KiK_i increases with [E], requiring quadratic corrections for accurate determination. Dixon plots serve as a key diagnostic tool for KiK_i determination by plotting 1/v1/v versus [I] at two or more fixed [S] values, yielding straight lines whose intersection at −Ki-K_i on the x-axis provides the for competitive inhibitors; for non-competitive, the equals 1/Vmax⁡1/V_{\max} and slope varies with [S]. This method assumes linear inhibition and fixed [S], allowing graphical extraction of KiK_i without nonlinear fitting, though it is sensitive to experimental error at low [I]. Modern analyses often complement Dixon plots with software for global fitting to confirm values.

Dissociation Constants and Binding

The dissociation constant KiK_i quantifies the equilibrium binding affinity of a reversible inhibitor to an , defined for the enzyme-inhibitor (EI) complex as Ki=[E][I][EI]K_i = \frac{[E][I]}{[EI]}, where [E] is the concentration of free , [I] is the concentration of free inhibitor, and [EI] is the concentration of the enzyme-inhibitor complex. This constant reflects the strength of non-covalent interactions at equilibrium, with lower KiK_i values indicating tighter binding and higher inhibitory potency. The thermodynamic favorability of inhibitor binding is linked to the standard change (ΔG∘\Delta G^\circ) via the relation ΔG∘=−RTln⁡(1/Ki)\Delta G^\circ = -RT \ln(1/K_i), where RR is the and TT is the absolute temperature; a more negative ΔG∘\Delta G^\circ corresponds to a smaller KiK_i and spontaneous binding under standard conditions. This equation underscores how binding free energy drives the stability of the EI complex, influencing inhibitor design by targeting energetically favorable interactions. Binding isotherms, which plot the fraction of enzyme bound to inhibitor (θ=[EI][E]t\theta = \frac{[EI]}{[E]_t}, where [E]_t is total enzyme concentration) against inhibitor concentration, provide a direct measure of affinity and are typically hyperbolic for simple 1:1 binding. Scatchard plots, derived from these isotherms as θ[I]\frac{\theta}{[I]} versus θ\theta, linearize the data for non-cooperative binding, yielding KiK_i from the slope (equal to 1/Ki1/K_i) and the x-intercept (related to binding site number); deviations from linearity indicate multiple binding sites or cooperativity. The value of KiK_i is profoundly influenced by the inhibitor's molecular , particularly through non-covalent forces such as hydrogen bonding, which provides specificity by forming directional interactions between polar groups on the inhibitor and residues; van der Waals forces, contributing to hydrophobic packing and shape complementarity; and electrostatic interactions, including salt bridges or charge-charge attractions that stabilize the complex in aqueous environments. For instance, inhibitors mimicking substrate geometry often achieve low nanomolar KiK_i values by optimizing these interactions within the . In cases of allosteric inhibitors, binding can exhibit , where the affinity at one site modulates affinity at others, quantified by the Hill coefficient (nHn_H) in the generalized binding equation θ=[I]nHKnH+[I]nH\theta = \frac{[I]^{n_H}}{K^{n_H} + [I]^{n_H}}; nH>1n_H > 1 indicates positive , enhancing sensitivity to inhibitor concentration, while nH<1n_H < 1 suggests negative . This phenomenon arises from conformational changes propagated through the structure, as seen in regulatory enzymes where allosteric inhibitors amplify inhibitory effects.

Special Cases in Reversible Inhibition

Partially Competitive and Slow-Tight Inhibitors

Partially competitive inhibitors represent a subset of reversible inhibitors that bind to the of the free , thereby competing with the substrate for binding, yet permit the formation of a productive -substrate-inhibitor (ESI) ternary complex with diminished catalytic efficiency. This mechanism contrasts with classical by allowing residual enzyme activity even in the presence of inhibitor, resulting in an apparent increase in the Michaelis constant (KmK_m) and a partial decrease in the maximum (Vmax⁡V_{\max}). The binding of the inhibitor to the (E + I ⇌ EI) is reversible, and the EI complex can subsequently bind substrate (S) to form ESI, which undergoes at a reduced rate compared to the binary -substrate (ES) complex. The kinetic behavior of partially competitive inhibition is captured by a modified Michaelis-Menten equation that accounts for the partial productivity of the ESI complex: v=Vmax⁡[S]Km(1+[I]Ki)+[S](1+[I]βKi)v = \frac{V_{\max} [S]}{K_m \left(1 + \frac{[I]}{K_i}\right) + [S] \left(1 + \frac{[I]}{\beta K_i}\right)} Here, KiK_i is the for the EI complex, and β\beta (where 0<β<10 < \beta < 1) quantifies the fractional catalytic activity of ESI relative to ES, reflecting the slow within the ternary complex. This equation arises from steady-state assumptions in the reaction scheme, where the inhibitor increases the apparent KmK_m by a factor of (1+[I]/Ki)(1 + [I]/K_i) while reducing Vmax⁡V_{\max} to βVmax⁡\beta V_{\max} at high substrate concentrations. Graphical analyses, such as Dixon plots, show convergence of lines at points offset from the origin, distinguishing partial from complete inhibition. Slow-tight inhibitors, also known as slow-binding inhibitors with high affinity, are reversible inhibitors where the association and dissociation rates are sufficiently slow relative to the enzyme's catalytic turnover, causing the inhibition to develop gradually over the timescale of the assay. This kinetic profile can initially resemble irreversible inhibition, as the enzyme-inhibitor (EI) complex forms slowly, leading to time-dependent loss of activity rather than instantaneous equilibrium. The underlying mechanism typically involves a two-step binding process: a rapid initial encounter complex (E + I ⇌ EI) followed by a rate-limiting isomerization to a tighter complex (EI ⇌ EI*), often driven by a conformational change in the enzyme. The overall equilibrium dissociation constant (KiappK_i^{app}) is tight (low nanomolar range), but the slow on-rate (konk_{on}) dominates the observed kinetics. Measuring slow-tight inhibition poses challenges for conventional steady-state methods, as the assumption of rapid equilibrium fails; instead, full progress curve analysis is required, monitoring product formation over time to fit parameters like kobsk_{obs} (observed pseudo-first-order rate constant), which varies hyperbolically with inhibitor concentration. Preincubation of and inhibitor prior to substrate addition helps distinguish slow-binding from substrate depletion effects, and the Morrison equation is commonly used to derive microscopic rate constants: kobs=k−3+(k3+k−3[I])([E]t+[I]−Kiapp)2[E]t−((k3+k−3[I])([E]t+[I]−Kiapp)2[E]t)2−k3[I][E]t([E]t+[I]+Kiapp)k_{obs} = k_{-3} + \frac{(k_3 + k_{-3} [I])([E]_t + [I] - K_i^{app})}{2 [E]_t} - \sqrt{ \left( \frac{(k_3 + k_{-3} [I])([E]_t + [I] - K_i^{app})}{2 [E]_t} \right)^2 - \frac{k_3 [I]}{[E]_t} ([E]_t + [I] + K_i^{app}) }
Add your contribution
Related Hubs
User Avatar
No comments yet.